Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OH) in one or both eyes.~* IOP requirements at Visit 3, A mean/median IOP ≥ 26 mmHg at a minimum of 1 time point, ≥ 24 mmHg at a minimum of 1 time point, and ≥ 22 mmHg at 1 time point in the same eye, and Mean/median IOP ≤ 32 mmHg in both eyes at all 3 measurement time points.~* Subjects with best-corrected visual acuity (BCVA), using Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent \~20/100) or better in either eye.~Exclusion Criteria:~* Subjects with a known hypersensitivity or contraindications to latanoprost or any of the ingredients in the study drugs.~* Subjects with known contraindications to nitric oxide (NO) treatment.~* Subjects whose central corneal thickness was greater than 600um in either eye.~* Subjects with any condition that prevented reliable applanation tonometry in either eye.~* Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.~* Subjects with previous or active corneal disease.~* Subjects with a history of severe dry eye.~* Subjects with monophthalmia.~* Subjects with optic disc hemorrhage.~* Subjects with a history of central retinal vein and artery occlusion.~* Subjects with a history of macular edema.~* Subjects with any intraocular infection, inflammation, or laser surgery within the previous 6 months from Visit 1 (Screening).~* Subjects who had incisional ocular surgery or severe trauma within the previous 6 months from Visit 1 (Screening).~* Subjects with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and subjects with angle closure, congenital and secondary glaucoma, and subjects with history of angle closure in either eye.~* Subjects with a diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects who were expected to require treatment with ocular or systemic corticosteroids.~* Subjects who were in need of any other topical or systemic treatment of OAG or OHT.~* Subjects with an anticipated need to initiate or modify medication (systemic or topical) that was known to affect IOP during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOL-303259-X (Type: EXPERIMENTAL): ophthalmic solution
- Latanoprost (Type: ACTIVE_COMPARATOR): ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).